Description
Semaglutide Tablets Description
Product name: Semaglutide tablets (Novo Nordisk/Rybelsus)
Packaging specifications: 7mg*10 tablets Product dosage form: tablets Packaging unit: box
Approval number: National Medicine Standard SJ20240005 Drug standard code: 86978997003475
Manufacturer: Novo Nordisk A/S, Denmark
Rybelsus® (semaglutide) 7mg oral tablet is the world’s first approved GLP-1 receptor agonist in pill form, designed to improve glycemic control and support weight management in adults with type 2 diabetes. It mimics the incretin hormone GLP-1 to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.
This innovative formulation uses an absorption enhancer (SNAC) to deliver semaglutide systemically — a breakthrough in peptide-based oral drug design.
Semaglutide Tablets Product Specifications
| Feature | Details |
|---|---|
| Product Name | Semaglutide Tablets (Rybelsus®) |
| Strength | 7mg per film-coated tablet |
| Packaging | 10 tablets per box |
| Dosage Form | Oral tablet |
| Manufacturer | Novo Nordisk A/S |
| Approval Number | NMPA: SJ20240005 (China) |
| Product Code | 86978997003475 |
| Barcode | — |
| Origin | Denmark |
| Storage Conditions | Store 30°C, protect from moisture and light |
| Shelf Life | As labeled |
| Administration | Once daily on empty stomach with 120ml water; wait 30–60min before food |
| Intended Use | For laboratory or analytical research only |
Semaglutide Tablets Mechanism & Clinical Highlights
GLP-1RA action: Boosts insulin, suppresses glucagon, delays gastric emptying, and reduces appetite.
Approved dosing: 3mg initial, titrating to 7mg — with demonstrated HbA1c reductions of –1.0% (7mg) and –1.3% (14mg) compared to sitagliptin.
Safety profile: Common side effects include nausea, diarrhea, and mild hypoglycemia (when used with other agents).
Pharmacokinetic note: Oral bioavailability is 0.4–1%, while injectable forms have ~89%, requiring oral dose adjustments.
Why Choose Rybelsus® Semaglutide Tablets?
Global innovations: The first oral GLP-1RA with established clinical approval
Peptide delivery breakthrough: Oral SNAC-enhanced peptide absorption
Lab-ready film tablets: Precise dosage, stable, and easy to store
Supporting research: Excellent for appetite, weight, and metabolic studies
Semaglutide Injection (Ozempic® / Wegovy®)
Exenatide, Dulaglutide – GLP?1RA injectables
Metformin, Dapagliflozin – Oral antidiabetic agents
Summary
Rybelsus® Semaglutide 7mg tablets represent a pharmacological milestone — the first oral GLP-1 receptor agonist suitable for advanced metabolic, endocrinology, and appetite-control research. Produced by Novo Nordisk, with global regulatory backing and innovative peptide delivery, it’s perfect for labs exploring GLP-1PA mechanisms.


mnsdz –
Received it, but the logistics took too long, I waited for 12 days
djinie –
Awesome, my brother